Trial Profile

A Randomized, 6-week, Double-blind, Placebo-controlled, Fixed-dose, Parallel Group Study of Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 11 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lurasidone (Primary)
Indications Major depressive disorder
Focus Therapeutic Use
Acronyms RESOLVE-2
Sponsors Sunovion Pharmaceuticals

Most Recent Events

10 Nov 2015 Primary endpoint has been met. (Montgomery-Asberg Depression Rating Scale)
10 Nov 2015 Results published online in the American Journal of Psychiatry.
10 Nov 2015 Status changed from withdrawn prior to enrolment to completed, as reported in the American Journal of Psychiatry.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com